Singapore Tissue Diagnostics Market Size, Share, and COVID-19 Impact Analysis, By Technology (In Situ Hybridization, Primary & Special Staining, Digital Pathology & Workflow, Immunohistochemistry, Anatomic Pathology, Molecular Pathology, and Others), By Application (Breast Cancer, Prostate Cancer, Non-Small Cell Lung Cancer, Gastric Cancer, and Others), By End Use (Hospitals, Diagnostic Centers, CROs, Pharmaceutical Organizations, and Others), and Singapore Tissue Diagnostics Market Insights, Industry Trend, Forecasts to 2035

Singapore Tissue Diagnostics Market Insights Forecasts to 2035

• The Singapore Tissue Diagnostics Market Size Was Estimated at USD 19.62 Million in 2024
• The Singapore Tissue Diagnostics Market Size is Expected to Grow at a CAGR of Around 11.02% from 2025 to 2035
• The Singapore Tissue Diagnostics Market Size is Expected to Reach USD 61.99 Million by 2035

According to a Research Report Published by Spherical Insights & Consulting, The Singapore Tissue Diagnostics Market Size is Anticipated to Reach USD 61.99 Million by 2035, Growing at a CAGR of 11.02% from 2025 to 2035. The Singapore Tissue Diagnostics market is driven by rising cancer and chronic disease prevalence, strong government-backed R&D, demand for precision and non-invasive diagnostics, advanced biotechnology infrastructure, and growing adoption of exosome-based therapeutics and liquid biopsy technologies.

Market Overview

The Singapore Tissue Diagnostics Market Size covers the activities of research, manufacture, distribution, and clinical application of various technologies and services that are used to examine tissue specimens for the detection, classification, and prediction of diseases in a more precise manner. It is a very important tool in the diagnosis of cancer, autoimmune diseases, infectious diseases, and genetic disorders. This market offers reagents, instruments, digital pathology systems, and software packages implemented in immunohistochemistry (IHC), in situ hybridization (ISH), molecular pathology, histopathology, and digital image analysis. Tissue diagnostics in Singapore is a field that is well supported by the presence of advanced hospital laboratories, research institutes, and experienced pathologists, which are geared towards early diagnosis, personalized treatment planning, and better patient outcomes.

Singapore Tissue Diagnostics Market Size plays a crucial role due to the nation facing a heavy disease burden and an aging population. One of the major health issues is cancer, with an average annual diagnosis of 25,000 new cases, resulting in a high demand for precise tissue-based diagnostics such as histopathology, IHC, and molecular testing. Also, it is estimated that about 25% of the total population in Singapore will be over 65 years old by 2030, which will lead to a rise in chronic and age-related diseases. These conditions depend significantly on tissue diagnostics for their early detection and treatment planning.

The market adoption and growth potential of tissue diagnostics seem highly dependent on government funding and national health care strategies. Through the RIE 2025 Plan, Singapore has earmarked SGD 25 billion for R&D, among which a sizable chunk has been allocated for healthcare, diagnostics, and precision medicine. Besides the training of NMRC and the National Precision Medicine Programme, preventive programs like Healthier SG serve as vehicles for getting advanced diagnostics into the hands of patients. In sum, the combination of increasing clinical demand, robust public financing, and policy incentives makes tissue diagnostics a vital and rapidly expanding segment of Singapore's healthcare and precision medicine landscape.

Report Coverage

This research report categorizes the market for the Singapore Tissue Diagnostics Market Size based on various segments and regions, and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Singapore tissue diagnostics market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Singapore tissue diagnostics market.

Driving Factors

The Singapore market for tissue diagnostics is mainly driven by a growing cancer burden, with approximately 25,000 new cases each year. The aging of the population is occurring at an accelerated rate, which is estimated to have 25% of people aged 65+ by 2030. The government's commitment to providing funds through the SGD 25 billion RIE 2025 plan, the increasing use of precision medicine and biomarkers, the innovations in digital pathology and AI, and the fact that Singapore has a mature healthcare and diagnostic infrastructure.

Restraining Factors

The Singapore Tissue Diagnostics Market Size is restrained by several factors, which include high costs of sophisticated diagnostic instruments and reagents, a shortage of highly skilled pathologists and trained laboratory professionals, and difficulties in the integration of digital pathology and AI systems with the hospital workflows that already exist. In addition, due to the smaller patient volumes in comparison with larger countries, it is unlikely that the market will be able to achieve large-scale commercialization and cost efficiency.

Market Segmentation

The Singapore Tissue Diagnostics Market share is classified into technology, application, and end use.

• The immunohistochemistry segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. 

The Singapore Tissue Diagnostics Market Size is segmented by technology into in situ hybridization, primary & special staining, digital pathology & workflow, immunohistochemistry, anatomic pathology, molecular pathology, and others. Among these, the immunohistochemistry segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. The immunohistochemistry segment is growing because of its essential role in cancer diagnosis and biomarker testing, rising cancer cases, increasing use of targeted and immunotherapies, and advancements in automated IHC technologies that improve accuracy and efficiency.

• The breast cancer segment dominated the market in 2024 and is anticipated to grow at a substantial CAGR during the forecast period.

The Singapore Tissue Diagnostics Market Size is segmented by application into breast cancer, prostate cancer, non-small cell lung cancer, gastric cancer, and others. Among these, the breast cancer segment dominated the market in 2024 and is anticipated to grow at a substantial CAGR during the forecast period. The breast cancer segment is growing because breast cancer is one of the most commonly diagnosed cancers among women in Singapore, driving high demand for biopsy-based diagnosis, immunohistochemistry, and molecular testing. Increased screening programs, early detection initiatives, and adoption of biomarker-based personalized therapies further support the strong growth of tissue diagnostics in this segment.

• The hospitals segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. 

The Singapore Tissue Diagnostics Market Size is segmented by end use into hospitals, diagnostic centers, CROs, pharmaceutical organizations, and others. Among these, the hospitals segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. The hospital segment is growing due to the high volume of patient admissions, availability of advanced pathology laboratories, and increasing demand for in-house tissue diagnostics for cancer diagnosis and treatment planning. Strong government investment in public hospitals, adoption of precision medicine, and integration of digital pathology technologies further support segment growth.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Singapore Tissue Diagnostics Market Size , along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Roche Diagnostics
• Leica Biosystems
• Thermo Fisher Scientific
• Abbott Laboratories
• Agilent Technologies
• Merck KGaA
• Bio-Rad Laboratories
• Innoquest Diagnostics Pte Ltd
• Pathology Asia Holdings
• Raffles Diagnostics
• Quest Laboratories Pte Ltd
• Qritive
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments:

• In October 2025, Singapore’s National University Hospital (NUH) and NUS Medicine launched a Molecular Imaging and Theranostics Centre featuring the country’s first total-body PET/CT scanner, boosting precision diagnostics and research, and expected to serve about 2,900 patients annually, enhancing cancer detection and translational studies.

Market Segment

This study forecasts revenue at the Singapore, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Singapore Tissue Diagnostics Market Size based on the below-mentioned segments:

Singapore Tissue Diagnostics Market, By Technology

• In situ Hybridization
• Primary & Special Staining
• Digital Pathology & Workflow
• Immunohistochemistry
• Anatomic Pathology
• Molecular Pathology
• Others

Singapore Tissue Diagnostics Market, By Application

• Breast Cancer
• Prostate Cancer
• Non-Small Cell Lung Cancer
• Gastric Cancer
• Others

Singapore Tissue Diagnostics Market, By End Use

• Hospitals
• Diagnostic Centers
• CROs
• Pharmaceutical Organizations
• Others